Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.
Alzforum,
Igarashi A, Azuma MK, Zhang Q, Ye W, Sardesai A, Folse H, Chavan A, Tomita K, Tahami Monfared AA.
Igarashi A, Azuma MK, Zhang Q, Ye W, Sardesai A, Folse H, Chavan A, Tomita K, Tahami Monfared AA.
BioArctic AB’s (publ) partner Eisai announced that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand…
The paper concluded that lecanemab treatment would improve health and humanistic (quality of life) outcomes and reduce medical…
/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of results from…